Skip to main content

Table 2 Summary table of CNS best response by composite criteria among evaluable patients

From: Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases

Response All (n = 38) Cohort 1 (HER2-negative) (n = 9) Cohort 2 (HER2-positive) (n = 29)
No. of patients (%) No. of patients (%) No. of patients (%)
CR 0 (0) 0 (0) 0 (0)
PR 24 (63)a 5 (56) 19 (66)
SD > 24 weeks 2 (5) 0 (0) 2 (7)
SD < 24 weeks 5 (13) 0 (0) 5 (17)
PDb 7 (18) 4 (44) 3 (10)
 PD in CNS by radiographic criteria 1 (3) 0 (0) 1 (3)
 Symptomatic deterioration 2 (5) 1 (11) 1 (3)
 PD in non-CNS site(s) 4 (11) 3 (33) 1 (3)
  1. aTaking into account the two-stage design, the 95% CI for CNS ORR (n = 38) is 47 to 77%
  2. bPatients were considered to have progressed if any of the PD criteria were met. Each patient could also have been taken off study for meeting multiple PD criteria simultaneously
  3. Abbreviations: CNS central nervous system, CR complete response, HER2 human epidermal growth factor receptor 2, PD progression of disease, PR partial response, SD stable disease